Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients

Cyclosporin A is increasingly used in the treatment of severe refractory atopic dermatitis. Although cyclosporin A treatment is highly efficacious and relatively safe, we report four adult atopic dermatitis (AD) patients who deteriorated during long-term cyclosporin A treatment, with clinical signs and symptoms more severe than at the onset of treatment. Interestingly, these patients showed large increases of total serum immunoglobulin E (IgE) levels, paralleled by increasing disease severity and serum levels of thymus and activation-regulated chemokine. This implies that cyclosporin A may induce a shift to Th2, resulting in increased IgE synthesis, in a ubpopulation of AD patients. We therefore suggest that in this subpopulation, treatment with anti-B cell or combined anti-B and T-cell treatment may be favorable.